Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;11(1):32-38.
doi: 10.1080/21541248.2017.1336193. Epub 2017 Jul 7.

Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers

Jordan M Thompson  1 , Jaime Landman  2 , Olga V Razorenova  1
Affiliations
Review

Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers

Jordan M Thompson et al. Small GTPases. 2020 Jan.

Abstract

The loss of the von Hippel-Lindau (VHL) tumor-suppressor is a major driver of Clear Cell Renal Cell Carcinoma (CC-RCC) resulting in the stabilization and overactivation of hypoxia inducible factors (HIFs). ROCK1 is a well-known protein serine/threonine kinase which is recognized as having a role in cancer including alterations in cell motility, metastasis and angiogenesis. We recently investigated and identified a synthetic lethal interaction between VHL loss and ROCK1 inhibition in CC-RCC that is dependent on HIF overactivation. Increased expression and activity of both HIFs and ROCK1 occurs in many types of cancer supporting the potential therapeutic role of ROCK inhibitors beyond CC-RCC. We also discuss future research required to establish prognostic markers to predict tumor response to ROCK inhibitors.

Keywords: Clear Cell Renal Cell Carcinoma; HIF; ROCK1; Rho; VHL; synthetic lethality.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overview of VHL/HIF and Rho/ROCK signaling pathways. VHL, left, is a part of an E3 ubiquitin ligase complex that targets HIF-1α and HIF-2α for degradation. The loss of VHL stabilizes HIFs, leading to elevated expression of a multitude of HIF-target genes, involved in angiogenesis, migration, invasion, glycolysis, etc. ROCK signaling, right, is dependent on activation by RhoGTPases that bind to ROCK1 and ROCK2. ROCK family kinases are major regulators of actin organization within the cell controlling actin filament stabilization, actomyosin contraction, actin cytoskeleton rearrangements, microtubule stabilization, etc. The combination of VHL loss leading to HIF overactivation and Rho/ROCK pathway inhibition triggers synthetic lethality.
See this image and copyright information in PMC

References

    1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Prim 2017; 3:17009; PMID:28276433; https://doi.org/ 10.1038/nrdp.2017.9 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Cancer J Clin 2016; 66:7-30; https://doi.org/ 10.3322/caac.21332 - DOI - PubMed
    1. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, et al.. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41; PMID:15625368; https://doi.org/ 10.1200/JCO.2005.03.206 - DOI - PubMed
    1. Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al.. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 456:125-34; https://doi.org/ 10.1056/NEJMoa060655 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al.. Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-31; PMID:23964934; https://doi.org/ 10.1056/NEJMoa1303989 - DOI - PubMed

Publication types

MeSH terms

Substances